Lachlan Hanbury Brown
Stock Analyst at William Blair
(0.61)
# 4,140
Out of 4,609 analysts
125
Total ratings
36.4%
Success rate
-3.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Lachlan Hanbury Brown
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRDN Viridian Therapeutics | Maintained: Buy | n/a | $22.16 | - | 10 | Aug 6, 2026 | |
| OCUL Ocular Therapeutix | Maintained: Buy | n/a | $8.73 | - | 17 | Aug 3, 2026 | |
| TSX: EPRX Eupraxia Pharmaceuticals Inc. | Maintained: Buy | n/a | $9.17 | - | 5 | Jul 31, 2026 | |
| HROW Harrow | Maintained: Buy | n/a | $39.72 | - | 18 | Jul 20, 2026 | |
| KLRS Kalaris Therapeutics | Maintained: Buy | n/a | $4.17 | - | 12 | Jul 17, 2026 | |
| TARS Tarsus Pharmaceuticals | Maintained: Buy | n/a | $64.50 | - | 13 | Jul 14, 2026 | |
| SPRY ARS Pharmaceuticals | Maintained: Buy | n/a | $5.49 | - | 27 | Jul 9, 2026 | |
| LENZ LENZ Therapeutics | Maintained: Buy | n/a | $5.27 | - | 19 | Jul 6, 2026 | |
| SLDB Solid Biosciences | Maintained: Buy | n/a | $8.80 | - | 2 | Mar 20, 2026 | |
| ZVRA Zevra Therapeutics | Maintained: Buy | n/a | $11.69 | - | 2 | Mar 16, 2026 |
Viridian Therapeutics
Aug 6, 2026
Maintained: Buy
Price Target: n/a
Current: $22.16
Upside: -
Ocular Therapeutix
Aug 3, 2026
Maintained: Buy
Price Target: n/a
Current: $8.73
Upside: -
Eupraxia Pharmaceuticals Inc.
Jul 31, 2026
Maintained: Buy
Price Target: n/a
Current: $9.17
Upside: -
Harrow
Jul 20, 2026
Maintained: Buy
Price Target: n/a
Current: $39.72
Upside: -
Kalaris Therapeutics
Jul 17, 2026
Maintained: Buy
Price Target: n/a
Current: $4.17
Upside: -
Tarsus Pharmaceuticals
Jul 14, 2026
Maintained: Buy
Price Target: n/a
Current: $64.50
Upside: -
ARS Pharmaceuticals
Jul 9, 2026
Maintained: Buy
Price Target: n/a
Current: $5.49
Upside: -
LENZ Therapeutics
Jul 6, 2026
Maintained: Buy
Price Target: n/a
Current: $5.27
Upside: -
Solid Biosciences
Mar 20, 2026
Maintained: Buy
Price Target: n/a
Current: $8.80
Upside: -
Zevra Therapeutics
Mar 16, 2026
Maintained: Buy
Price Target: n/a
Current: $11.69
Upside: -